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Résumé 
Introduction 
L'ostéogenèse imparfaite (OI) est une maladie osseuse héréditaire qui affecte la production du 
collagène de type I et le remodelage osseux. Les biphosphonates sont administrés aux enfants 
atteints d'OI dans le but d’augmenter la masse osseuse et de réduire les fractures osseuses. Les 
patients atteints d’OI ont des malocclusions sévères qui affectent leur qualité de vie. Plusieurs 
processus biologiques de remodelage osseux qui sont nécessaires pour un mouvement dentaire 
orthodontique sont affectés chez les gens atteints d’OI. L'objectif de cette étude est d'évaluer le 
mouvement dentaire orthodontique dans un modèle de souris avec OI et traitées aux 
biphosphonates. 
Matériels et méthodes 
Vingt-quatre souris femelles âgées de 10 semaines ont été divisés en 4 groupes :  
1 - OI traitées par zolédronate (n=6); 2 - OI non traitées (n=6); 3 - Type sauvage traitées par 
zolédronate (n=6); 4 – Type sauvage non traitées (n=6) 
Un ressort de nickel-titane activé à 10 g de force a été cimenté entre les incisives et la 1ère 
molaire maxillaire droite. Le côté contralatéral a été utilisé comme témoin. Une dose de 0,05 
mg de zolédronate a été administrée par voie sous-cutanée un jour avant la chirurgie. Sept 
jours après l'intervention, les souris ont été euthanasiées et la distance entre la 1ère et la 2e 
molaire a été mesurée par analyse microtomographique. 
Résultats 
Le mouvement dentaire orthodontique était significativement plus important chez les souris OI 
que celles de types sauvages dans les groupes non traités (p < 0,05). Le traitement par 
zolédronate n'a eu aucun effet significatif sur le mouvement dentaire orthodontique au sein des 
groupes OI et type sauvages. 
Conclusions 
Ces résultats suggèrent une augmentation du mouvement dentaire orthodontique chez les 
souris avec l’ostéogenèse imparfaite. 
Mots-clés : ostéogenèse imparfaite, mouvement dentaire orthodontique, souris, 
biphosphonates, micro-CT 
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Abstract 
INTRODUCTION 
Osteogenesis imperfecta (OI) is a heritable bone disorder that affects collagen type I 
production and bone remodeling. Orthodontic tooth movement (OTM) involves the underlying 
process of alveolar bone remodeling. The objective of this study is to evaluate OTM in a 
mouse model of OI. 
METHODS 
Twenty four, 10 week-old female mice were divided into 4 groups: 1- OI treated with 
zoledronate, 2- OI untreated, 3- Wild-type (WT) treated with zoledronate and 4- WT 
untreated. A nickel-titanium closed coil spring (10 g) was attached between the incisors and 
the right maxillary 1st molar. The contralateral side was used as control. Zoledronate 
(0.05mg/kg) was administered sub-cutaneously 1 day prior to surgery. Seven days after the 
procedure, the distance between 1st – 2nd molars was measured by micro-CT.  
RESULTS 
OI mice presented significantly more OTM than WT mice when comparing within untreated 
groups (p<0.05). Zoledronate treatment had no significant effect on OTM within OI and WT 
groups. 
CONCLUSIONS 
These results suggest increased OTM in mice with OI. The dose of zoledronate administrated 
1 day prior to surgery had no significant effect on OTM. 
Keywords: osteogenesis imperfecta, orthodontic tooth movement, mice, bisphosphonates, 
micro-CT 
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Introduction 
Osteogenesis Imperfecta 
Overview 
Osteogenesis imperfecta (OI), also known as ‘brittle bone disease’, is a clinically 
heterogeneous heritable disorder affecting the connective tissue. It has a cumulative incidence 
of approximately 1 in 15,000-20,000 with the majority of patients having dominant mutations 
in the genes COL1A1 and COL1A2.1 Mutations in other genes, such as CRTAP and LEPRE1, 
lead to severe recessive forms of osteogenesis imperfecta. The severity is variable, ranging 
from a severe lethal form to milder forms without fractures. In general, the clinical 
manifestations are multiple fractures, muscle weakness, joint laxity, curved bones, blue sclera, 
hearing loss, presence of wormian bones on skull radiographs and dentinogenesis imperfecta 
(figure 1).  
 
Figure 1 Bowing of the radius (a) and tibia (b) in a baby with osteogenesis imperfecta type III2 
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Classification 
The original classification by Sillence et al in 1979 divided osteogenesis imperfecta 
into 4 types and is still the most widely used classification to date.  The classification has since 
been expanded to include the more recent types of OI. Bone fragility in the most important 
characteristic of all types of osteogenesis imperfecta, its severity increases in the following 
order: type I < types IV, V, VI, VII < type III < type II.3 
 
Table I Expanded Sillence classification of osteogenesis imperfecta3 
Type Clinical severity Typical features Typically 
associated 
mutations* 
I Mild non-deforming 
osteogenesis 
imperfecta 
 
Normal height or mild short stature; blue 
sclera; no dentinogenesis imperfecta 
Premature stop 
codon in COL1A1 
II Perinatal lethal Multiple rib and long-bone fractures at 
birth; pronounced deformities; broad long 
bones; low density of skull bones on 
radiographs; dark sclera 
 
Glycine 
substitutions in 
COL1A1 or 
COL1A2 
III Severely deforming Very short; triangular face; severe 
scoliosis; greyish sclera; dentinogenesis 
imperfecta 
Glycine 
substitutions in 
COL1A1 or 
COL1A2 
 
IV Moderately 
deforming 
Moderately short; mild to moderate 
scoliosis; grayish or white sclera; 
Glycine 
substitutions in 
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dentinogenesis imperfecta COL1A1 or 
COL1A2 
V Moderately 
deforming 
Mild to moderate short stature; 
dislocation of radial head; mineralised 
interosseous membrane; hyperplastic 
callus; white sclera; no dentinogenesis 
imperfecta 
 
Unknown 
VI Moderately to 
severely deforming 
Moderately short; scoliosis; accumulation 
of osteoid in bone tissue, fish-scale 
pattern of bone lamellation; white sclera; 
no dentinogenesis imperfecta 
 
Homozygous 
SERPINF1 
mutations 
VII Moderately 
deforming 
Mild short stature; short humeri and 
femora; white sclera; no dentinogenesis 
imperfecta 
 
Homozygous 
CRTAP mutations 
*May or may not be detectable in a given patient 
Oral manifestations 
Many oral manifestations are associated to osteogenesis imperfecta. Dentinogenesis 
imperfecta has been well documented in the literature. Many authors have reported an 
overrepresentation of Class III malocclusions, posterior and anterior openbites, crossbites and 
impacted teeth. Recently, our group showed that the patients with severe types of osteogenesis 
imperfecta have more severe malocclusions.4 One of the most challenging types of 
malocclusions that require early orthodontic treatment is the Class III malocclusion. This 
malocclusion is manifested by a more anterior position of the mandibular teeth relative to the 
maxillary teeth. In this type of bite, it is common for the lower anterior teeth to bite ahead of 
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the upper anterior teeth; this condition is also called anterior cross-bite. There are three causes 
of Class III malocclusions: an overdeveloped mandible (prognatism), an underdeveloped 
maxilla or a combination of both. Many environmental factors have been suggested as 
contributory to the development of mandibular prognatism. They include congenital anatomic 
defects, a habit of protruding the mandible, posture, hormonal disturbances and irregular 
eruption of the permanent incisors or loss of deciduous incisors. Substantial evidence has been 
advanced to support the theory of familial influence in mandibular prognatism and Class III 
malocclusion. 
Pathogenesis 
The pathogenesis of the forms of osteogenesis imperfecta with type 1 collagen 
mutations is well known. A collagen type I molecule comprises of 3 polypeptides (two α 1 
and one α 2 chain) that form a triple-helical structure.5 In order for the three chains to 
perfectly intertwine, there must be a glycine residue at every third position. The most typical 
sequence abnormality associated with osteogenesis imperfecta is a point mutation that affects 
a glycine residue in either COL1A1 or COL1A2.3 Cells enclosing this kind of mutation 
produce a mixture of normal and abnormal type I collagen. The resulting phenotype will be 
altered by which α chain is affected, the position in the triple helix at which the substitution 
arises, and which aminoacid is substituted for glycine. In most cases, mutations that form a 
premature stop codon within COL1A1 result in an osteogenesis imperfecta type I phenotype. 
Treatments 
Medical management of patients affected by osteogenesis imperfecta is directed by a 
multidisciplinary approach consisting of physical therapy, rehabilitation and orthopaedic 
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surgery. Till now, there is no cure for this disease. Physical activity is encouraged, with an 
increased risk of fracture, to prevent bone loss due to inactivity.6 Some patients require 
intramedullary rods surgically placed in their tibiae and femora in order to stand and walk.6 
Historically, pharmacological treatment of osteogenesis imperfecta has been unsuccessful. 
Three decades ago, Albright7 evaluated 96 reports of 20 different treatments including 
hormones (calcitonin, cortisone, oestrogens, androgens, and thyroxine), vitamins (A, C, and 
D), minerals (aluminium, calcium, fluoride, magnesium, phosphate, and strontium), and some 
more exotic approaches (such as arsenic, radiation, dilute hydrochloric acid, and calf-bone 
extract). Although researchers claimed some clinical effectiveness, none stood the test of 
time.3 
In 1987, Devogelear and colleagues reported pronounced clinical and radiological 
improvement in a case of a 12-year-old girl suffering from osteogenesis imperfecta and treated 
with oral pamidronate for 1 year. Pamidronate is a member of the bisphosphonate family of 
drugs, potent antiresorptive compounds that inhibit osteoclastic activity. Bisphosphonates are 
administered to children with osteogenesis imperfecta with the rationale that an increased bone 
mass will reduce bone fractures. Traditionally intravenous pamidronate has been used in 
children, however newer bisphosphonates with greater potency such as zoledronic acid have 
started to be used in clinical practice.2 
 
Bisphosphonates 
 Overview 
Bisphosphonates (BPs) are commonly used to treat patients with metabolic bone 
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diseases such as osteoporosis or in malignomas and bone metastases. Bisphosphonates have an 
inhibitory effect on osteoclasts and thus decrease bone resorption. All bisphosphonates contain 
two phosphate groups attached to a single carbon atom to form a P-C-P core structure (figure 
2).8 They are stable analogues of pyrophosphate compounds, which are commonly found in 
nature. Inorganic pyrophosphates are the simplest, naturally occurring pyrophosphates.9 
Bisphosphonates differ from inorganic pyrophosphates (P–O–P) in that the oxygen has been 
replaced by a non-hydrolysable carbon. The phosphate and hydroxyl group create a tertiary 
interaction between the BP and the bone matrix, giving BPs their specificity for bone. 
Bisphosphonates also have a high affinity for bone mineral, allowing them to achieve a high 
local concentration throughout the entire skeleton.10 The half-life can exceed 10 years.11 
 
Figure 2 Chemical structure of bisphosphonates.8 The two phosphonate groups form covalent 
bonds to the carbon atom. The carbon atom forms two other covalent bonds, the resulting R1 
and R2 chains. The P-C-P core is responsible for the high affinity of BPs to calcium ions. 
Bisphosphonates reduce the risk of fracture by inhibiting osteoclastic activity, thus reducing 
bone remodeling and increasing bone mineral density.  
 
Bisphosphonates are readily adsorbed to the mineral surface of the bone and cleared 
from the circulation. Their preference to bone rather than soft tissue brings them into close 
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contact with osteoclasts.  This results in biphosphonates being stored in the bone and only 
released during bone resorption. There are many mechanisms by which bisphosphonates can 
affect osteoclast-mediated bone resorption (figure 3). The most likely route through which 
bisphosphonates inhibit bone resorption is by their direct effects on mature osteoclasts.8 In 
addition to affecting mature osteoclasts, bisphosphonates can inhibit bone resorption by 
preventing osteoclast formation. Previous studies have demonstrated that some 
bisphosphonates can inhibit the formation of osteoclasts, probably by preventing the fusion of 
osteoclast precursors.9 
 
Figure 3 Mechanisms by which biphosphonates inhibit bone resorption8 
 
Nitrogen containing bisphosphonates, such as pamidronate and zoledronate, are taken 
up by the osteoclasts and inhibit farnesyl pyrophosphotase synthase, an enzyme of the 
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mevalonate pathway. This leads to the inhibition of isoprenoid geranyl pyrophosphate and 
thereby of the prenylation of small GTP-binding proteins (i.e.,Ras and Rho) that are 
responsible for cytoskeletal integrity and intracellular signaling (figure 4).8 The consequence 
of these events initiates a series of results including the suppression of osteoclastic activity, 
loss of osteoclast cytoskeletal integrity and ruffled border, and ultimately apoptosis.8 
 
Figure 4 Molecular effect of bisphosphonates.8 Nitrogen-containing bisphosphonates mediate 
their action by inhibiting the mevalonate pathway involved in cholesterol synthesis. 
Bisphosphonates inhibit farsnesylpyrophosphate (Farnesyl-PP) synthase, an enzyme that 
catalyzes conversion of geranylpyrophosphate to farnesylpyrophosphate. 
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Bisphosphonate-related osteonecrosis of the jaw 
 
A significant complication related to bisphosphonate use is osteonecrosis of the jaw. 
The incidence of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in osteoporotic 
patients treated with oral bisphosphonates is very low, with an estimated 0-0.04%.12 In a study 
by Marx et al.13 one hundred and nineteen cases of BRONJ were thoroughly reviewed. The 
vast majority of patients were treated for cancer. Aggravating factors included smoking, 
alcohol use, and ongoing chemotherapy. Migliorati et al.14 reported BRONJ in 17 cases of 
cancer patients receiving intravenous zoledronate or pamidronate.  There were 2 spontaneous 
cases but the rest appeared following an oral surgical procedure, primarly dental extractions.  
There has yet to be a case of BRONJ reported in children. Also, no cases of osteonecrosis of 
the jaw have been reported in patients with osteogenesis imperfecta.15 
Orthodontic considerations 
 
Successful orthodontic therapy is dependant on bone remodeling. In order to move 
teeth, adequately functioning osteoblasts and osteoclasts are required in the area surrounding 
the periodontal ligament. It would be logical to assume that an inhibition of osteoclastic 
activity would result in reduced tooth movement. In a study on 9-10 weeks old rats, a 3-week 
systemic bisphosphonate treatment reduced tooth movement by 40%.16 In a study on mice, a 
daily local injection of bisphosphonates for 12 days reduced the amount of tooth movement 
and the number of osteoclasts. In addition, it also reduced root resorption.17 In 2005, 
Schwartz18 reported a case of a female orthodontic patient treated with bisphosphonates to 
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control bone metastases related to breast cancer. When the patient initiated orthodontic 
therapy, the premolar spaces were one-third closed, however, no significant space closure was 
observed after bisphosphonate therapy was initiated. Rinchuse et al.19 described the 
orthodontic treatment and outcome of two patients who had received bisphosphonates. Both 
patients experienced impeded tooth movement and one patient also had osteonecrosis of the 
mandible. Recently, a pilot study from the University of Alberta has demonstrated that the 
bone burden from previous bisphosphonate use will significantly inhibit orthodontic tooth 
movement (OTM).20 It is reasonable to conclude that patients receiving bisphosphonate 
treatment pose a greater challenge to the orthodontist because of the possible inhibition of 
tooth movement and the potential of developing osteonecrosis of the jaw.  
 
Orthodontic tooth movement 
 
The general principle of orthodontic tooth movement is that if a prolonged force is 
applied to a tooth, tooth movement will occur as the surrounding bone remodels. Bone is 
selectively resorbed in some areas and added in other areas. Essentially, as the tooth migrates 
through the bone, it drags its attachment apparatus along with it. The periodontal ligament, the 
intermediate between the teeth and bone, mediates the bony response. According to Proffit, 
tooth movement is believed to be primarily a periodontal ligament phenomenon.  
Each tooth is attached to its supporting alveolar bone by a network of predominantly 
collagenous structure, the periodontal ligament. Although most of the space is taken up by 
collagen there are also two other major components of the ligament. There are the cellular 
elements, including various types of mesenchymal cells along with vascular and neural 
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elements; and tissue fluids. Both play an important role in normal function as well as allowing 
orthodontic tooth movement. 
The principal cells found in the periodontal ligament are fibroblasts, osteoblasts and 
their precursors, mesenchymal cells. During normal function, fibroblasts are constantly 
renewing the collagenous matrix. At the same time, osteoblasts are adding new bone to the 
dental socket. Bone and cementum are removed by specialized osteoclasts and cementoclasts, 
respectively. The periodontal ligament, though not highly vascular, does receive its nutrition 
through a vascular system. It is also important to recognize that the periodontal ligament is 
filled with fluid. Many describe the periodontal ligament as a gel-like shock absorber. 
Theories of tooth movement 
Proffit describes two main theories that attempt to explain orthodontic tooth 
movement. The bioelectric theory relates tooth movement to changes in bone metabolism that 
are dictated by the electric signals produced when alveolar bone is bended. The pressure-
tension theory relates tooth movement to cellular, chemical and blood flow changes in the 
periodontal ligament. The theories are not mutually exclusive, it would seem that both 
mechanisms might play a role in the biologic control of tooth movement. 
Electrical signals that could initiate tooth movement were thought to be piezoelectric. 
Piezoelectricity is a phenomenon that can be observed in any crystalline structure. Essentially 
piezoelectricity means a charge produced from pressure. Piezoelectricity has two unusual 
characteristics: 1- A quick decay rate and 2- The production of an equal and opposite charge 
when the force is released. Due to these characteristics, only rhythmic activity could generate 
an important exchange of electric signals, whereas constant forces would only produce a 
charge at the moment of application and release of the force. It would seem that this type of 
 12 
force is more important in the general maintenance of the skeleton and less so in orthodontic 
tooth movement. Another type of endogenous electric signal called the ‘‘bioelectric potential’’ 
can be observed in bone that is not being stressed. Although this process is not well known, 
cellular activity can be modified by the application of exogenous electric signals. In animal 
and human studies, it has been demonstrated that tooth movement can be accelerated when a 
low voltage current is applied.21 
The classical theory of orthodontic tooth movement, the pressure-tension theory, relies 
on chemical rather than electrical signals as the trigger to the cascade of events that ultimately 
lead to tooth movement. In this theory, an alteration in blood flow is caused by the movement 
of the tooth in the periodontal ligament space, creating areas of compression and areas of 
tension. Generally, blood flow is decreased in areas of compression while remaining constant 
or increased in the areas of tension. The alterations in blood flow quickly alter the chemical 
composition of the local environment. For example, oxygen levels are decreased in areas of 
low blood flow but might increase in areas of higher blood flow. These chemical changes, 
acting either directly or by stimulating the release of secondary messengers, then would 
stimulate cellular differentiation and activity. Essentially, this theory shows three stages; 1- 
alterations in blood flow, 2- the formation and/o release of chemical messengers, and 3- 
activation of cells (Table II).22 
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Table II Physiologic response to sustained pressure against a tooth22 
 
Factors influence tooth movement 
Orthodontic tooth movement is also modulated by the magnitude, the duration, the 
origin of application and the direction of the force. There are two different types of applied 
forces: continuous and intermittent. Contemporary orthodontic appliances are based on light 
continuous forces. The magnitude and the duration of forces have an important effect on the 
tissue response. Up to a certain stress level, the reactions occur mainly in the periodontal 
ligament with increasing vascularization, cell proliferation, fiber and bone formation but 
beyond that level, decreased vascularization and cell destruction occurs.  At a certain 
magnitude of continuous force, blood vessels appear completely occluded and a sterile 
necrosis ensues (figure 5). Different directions and application of the force will result in 
different types of movements. Movements are often presented in terms of tipping, translation 
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or bodily movement, intrusion, extrusion, rotation and torquing. 
 
Figure 5 Diagrammatic representation of the increasing compression of blood vessels as 
pressure increases in the PDL.22 At a certain magnitude of continuous pressure, blood vessels 
are totally occluded and a sterile necrosis of PDL tissue ensues.  
Biology of tooth movement 
 
At the cellular level, the application of forces on the crown of a tooth, may alter the 
internal forces acting on resident cells, leading to changes in gene expression, and production 
of proteins that ultimately alter the structure and function of the extracellular matrix, as well as 
the jaw bones.23 As previously mentioned, the most important macromolecules of the 
extracellular matrix are collagen (the most abundant), proteoglycans, laminin, fibronectin, 
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elastin, and hyaluronic acid. These molecules bind to cell adhesion foci to transfer signals 
intracellularly.24 Thus, we can consider the extracellular matrix as a tissue that relays 
extracellular and intracellular strains to effect changes in organ structure and function, through 
mechanotransduction. 
Bone cells, especially osteocytes, are sensitive to their environment. They play the 
important role of mechanosensing and transducing in response to mechanical stress.25 
Osteocytes are connected to one another and to cells of the bone surface by a network of 
cytoplasmic projections or dendrites. Soon after bone loading, osteocytic metabolism is 
altered. Many anabolic signals, such asnitric oxide, prostaglandins, and ATP, are released 
within seconds of osteocyte loading.26 This triggers a cascade of events capable of stimulating 
osteoblastogenesis. 
The fluid flow theory states that osteocytes are sensitive to strains evoked from locally 
displaced fluid in the canaliculi (figure 6).23 When loading occurs, interstitial fluid is squeezed 
through the thin layer of non-mineralized matrix surrounding the cell bodies and cell 
processes, resulting in local strain at the cell membrane and activation of the affected 
osteocytes.23 Osteocytes may also send signals to activate the bone resorption cascade through 
expression of NF-κB ligand, secretion of macrophage colony-stimulating factors and through 
their own apoptosis.23 It is now thought that osteocytes act as the chief mechanosensors in 
bone.  
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 Figure 6 Sequence of bone remodeling stages during orthodontic treatment.23 The roles 
played by osteocytes, osteoblasts, and osteoclasts are illustrated. 
 
Similarly to osteocytes in bone, fibroblasts mediate the changes in connective tissues in 
response to mechanical loading. Fibroblasts are thought to be mechanoresponsive, meaning 
that the mechanical stress that is transmitted through the extracellular matrix to the fibroblasts 
via integrins influence their morphology, cytoskeletal organization, proliferation, 
differentiation, and gene expression.27 They contain proteins at their surface, called focal 
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adhesion kinases, which act as stress gauges. Once loaded, fibroblasts generate a cascade of 
events that ultimately lead to collagen synthesis or collagen degradation (figure 7).23 
 
 Figure 7 The responses of periodontal ligament fibroblasts to orthodontic forces23 
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In summary, orthodontic forces strain the extracellular matrix and cells of the alveolar 
bone and periodontal ligament. Through mechanotransduction, changes in the form and 
function of the extracellular matrix, the cell membrane, the cytoskeleton, the nucleus and other 
cytoplasmic organelles trigger a cascade of events.28 Cell adhesion molecules, such as 
integrins, transmit the mechanical stress from the extracellular matrix into the cell and vice 
versa. This is the general process by which a mechanical stimulus is converted into a 
biological signal. These biochemical or electric signals are rapidly relayed to the nucleus. The 
outcome of these events is either stimulation or suppression of gene expression and protein 
synthesis (figures 8 & 9).  
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Figure 8 The sequence followed by cells and tissues in mechanosensing, transduction, and 
response23 
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Figure 9 The sequence of orthodontic tooth movement, illustrating the roles played by 
mineralized and non-mineralized tissues along with the associated blood vessels and neural 
elements23 
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Hypothesis and study aims 
 
The objective of the current study is first to evaluate orthodontic tooth movement in a 
mouse model with osteogenesis imperfecta. The research hypothesis was that orthodontic 
tooth movement would be inhibited in the OI mouse model. The reasoning was that 
orthodontic forces trigger a series of events that involve collagen metabolism, among others. 
The mutant collagen would create a ‘‘kink’’ in the chain, translating to an inhibition of tooth 
movement. We would not expect to see the normal patterns of apposed immature bone on the 
areas of tension and bone resorption on the areas of compression. 
A second theory involves the periodontal ligament. Orthodontic forces strain the 
extracellular matrix and cells of the alveolar bone and periodontal ligament. Through 
mechanotransduction, changes in the form and function of the extracellular matrix are relayed 
to the cells of the alveolar bone and periodontal ligament. The most abundant macromolecules 
of the extracellular matrix are collagen. We thought that the mutant collagen would make the 
ECM insensitive to orthodontic forces and thus impede mechanotransduction. An analogy 
could be made with driving a car with a stiff suspension compared to a car with a loose 
suspension. The threshold of orthodontic force to induce tooth movement would be much 
higher in the OI mice just like we do not feel small bumps while driving a car with a loose 
suspension. 
Another objective that was studied is the effect of bisphosphonates on orthodontic 
tooth movement. Specifically, we wanted to study the effect of one systemic dose of 
zoledronate, equivalent to one treatment given in humans affected by OI, administered one 
day pre-op. The general consensus in the orthodontic literature is that bisphosphonates have an 
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inhibitory effect on orthodontic tooth movement, at least in adults. Recent studies have also 
established a dose dependant association. In our study, we expected a limited inhibitory effect 
of the orthodontic tooth movement. The OI patients followed at the Montreal Shriners 
Hospital receive 2 doses per year and typically for many years. No equivalencies have yet 
been established between mice drug metabolism and humans. The researchers are aware that 
the bisphosphonate protocol used on mice in this study cannot be compared to the one given to 
humans. 
 
  
 
Materials and methods 
A novel mouse model of osteogenesis imperfecta was recently developed in a 
laboratory at the University of Toronto (Laboratory Dr. J. Aubin). A mutation in the COL1A1 
gene was obtained by N-nitroso-N-ethylurea exposure. The OI mouse model used in our study 
mimics type IV OI in humans. Genotyping was performed on all mice to confirm for the 
mutation. 
A total of 24 ten-week-old female mice were used. These mice were divided into 2 
groups: 12 FVB mice (wild type) and 12 Col1a1Jrt/+ (OI). They were further randomly divided 
into 2 groups: 6 mice of each group received a subcutaneous injection of 0.05 mg/kg 
zoledronate and 6 were injected with saline one day prior to the experiment (table III). A 5 
mm NiTi closed coil spring was expanded to produce 10 g of force and attached between the 
right first molar and the central incisors (figure 10).  
The mice were put under general anesthesia with a Ketamine/Xylazine/Acepromazine 
cocktail administered intraperitoneally (i.p.). The mouth was maintained open with Andy 
orthodontic elastics (3M, Unitek) extending from the operating table to the incisors. The teeth 
were then isolated by holding the tongue and cheeks with college pliers. The entire procedure 
was a 4-hand procedure. The first part of the procedure consisted of cementing the intra-oral 
coil spring to the 1st molar. Prior to cementation, the coil spring was adjusted to exert 10 g of 
force by a tension gauge. The 1st molar was etched with 37% phosphoric acid (Scotchbond, 
3M ESPE) for 20 seconds (figure 11). We then rinsed off the acid with a wet cotton pellet and 
dried the tooth surface with an air compressor. A bonding agent (Transbond plus self etching 
primer, 3M ESPE) was then applied to the tooth. Finally, the coil spring was cemented with a 
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flowable composite cement (Filtek Supreme Ultra, 3M ESPE) (figure 12). The second part of 
the procedure consisted of attaching the coil to the central incisors. To cement the coil on the 
incisors, the same manipulations as described above were used but on the incisors (figures 10 
and 13) 
Table III Group description 
 
WT: wild type, OI: osteogenesis imperfecta 
 
24 Total mice 
12 FVB (WT) 
6 Treated with zoledronate  6 Not treated 
12 Col1a1Jrt/+ (OI) 
6 Treated with zoledronate  6 Not treated 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Figure 10 NiTi coil cemented from right maxillary 1st molar to central incisors © Jean 
Rizkallah 
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Figure 11 Etching of right maxillary 1st molar © Jean Rizkallah 
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Figure 12 NiTi coil cemented on right maxillary 1st molar © Jean Rizkallah 
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Figure 13 Etching of central incisors © Jean Rizkallah 
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Figure 14 Trimming of lower incisors © Jean Rizkallah 
 
In order to minimize complications, the mice were given a soft food diet 3 days prior to 
cementing the orthodontic appliance and continued during the duration of the experiment. The 
lower incisors were also trimmed to minimize appliance breakage (figure 14). The 24 mice 
received daily injections of carprofen (5 mg/kg) and saline for the first 4 days. After 7 days, 
the mice were euthanized by CO2 in a gas chamber and the maxillas and mandibles were 
dissected and fixed in 4% paraformaldehyde and 0.1% glutaraldehyde for 24 hours and then 
washed in PB 0.1 M. The different timepoints are illustrated in figure 15. The calcified 
dissections were maintained in PB 0.1 M during micro-CT scanning to finally be embedded in 
methylmetacrylate (MMA). 
 30 
 
 
Figure 15 Study timeline  
 
The exclusion criteria were: broken or debonded coil and spacing between left 1st and 
2nd maxillary molars. 
The distance between the maxillary 1st molars and the 2nd molars were measured by 
micro-CT scans (figure 16). The maxillas were scanned with the skyscan 1172 (Bruker 
microCT) at 5 microns of resolution. We assumed that the teeth were contacting prior to the 
cementation of the appliance. Total movement was obtained by measuring the shortest 
distance between the molar surfaces in both sagittal and occlusal views. Since the results were 
practically the same in both views, only the sagittal measurements were kept for statistical 
purposes. The maxillary left side was also measured and used as control.  
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Figure 16 Illustration of measurement of tooth displacement by micro-CT scan. The red line 
represents the shortest distance between the 1st and 2nd molar; and was used as the measure of 
tooth displacement. © Jean Rizkallah 
 
Statistical analysis 
Statistical differences of the right and left sides were determined by using a related-samples 
Wilcoxon test (p<0.05). Statistical analysis of the data was obtained by using independent-
samples Kruskal-Wallis test (p<0.05). An intraclass correlation coefficient of 0.99 was 
calculated to test intrarater reliability, based on the measure for a set of 15 mice. This shows 
excellent reliability in the measurement method. 
  
 
Results  
Table IV describes the weight fluctuations for all 24 mice. A decrease in body weight was 
observed for the first 3 days but was quickly followed by an increase for the remainder of the 
experiment. Table V describes the average tooth movement measured for each group. 
Differences between left and right sides were statistically significant in all 4 groups 
(Wilcoxon, p≤0.028). On the experimental side, tooth movement was significantly higher in 
the OI group compared to the control (figures 17 and 18). No statistical difference was 
measured between the groups treated with zoledronate and the untreated groups. 
 
Table IV Individual weight fluctuations for all 24 mice 
Animal # 
(Group) 
Day 1 body 
weight (g) 
Day 2 body 
weight (g) 
Day 3 body 
weight (g) 
Day 4 body 
weight (g) 
Day 5 body 
weight (g) 
Day 6 body 
weight (g) 
Day 7 body 
weight (g) 
Group 1 (OI+Z)        
588 16.5 15.4 15.4 15.5 16.2 16.1 17.1 
589 17.3 15.1 13.7 15.3 16.6 17.5 17.3 
738 16.8 15.7 16.9 17.2 17.5 17.5 17.7 
746 18.3 16.7 17.3 18.0 18.4 18.9 18.7 
748 18.1 15.9 15.7 16.2 16.7 17.3 17.5 
751 18.0 17.7 17.3 17.4 17.8 17.9 17.7 
Group 2 (OI)        
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599 16.2 14.2 12.8 13.3 14.4 15.3 16.0 
702 14.9 13.4 13.5 13.8 14.0 14.4 14.4 
708 18.8 18.1 17.8 17.8 17.6 18.0 18.0 
715 18.7 17.7 18.2 18.4 18.5 19.2 19.5 
832 18.6 16.7 17.0 16.9 17.8 19.1 18.2 
834 19.6 17.0 17.9 18.7 19.5 19.6 19.3 
Group 3 (WT+Z)        
470 20.8 17.5 15.9 16.6 16.2 17.8 17.9 
484 21.0 17.7 17.1 17.6 18.4 19.1 18.6 
564 20.5 19.0 18.5 18.6 19.4 19.6 19.8 
565 22.8 20.9 19.4 18.9 19.1 20.2 20.9 
566 23.4 21.0 20.3 20.2 21.0 21.2 21.4 
568 24.9 22.2 20.7 21.7 22.4 22.8 23.3 
Group 4 (WT)        
452 21.7 18.6 18.1 19.2 19.1 19.2 18.9 
453 21.1 17.8 17.2 17.6 17.8 18.4 18.2 
553 19.8 18.2 18.2 17.5 17.8 18.2 18.5 
555 21.6 19.3 18.7 19.1 20.1 20.2 19.7 
559 21.0 19.1 19.3 18.8 20.2 20.9 20.9 
560 21.8 19.8 19.2 20.0 20.5 21.2 21.5 
WT: wild type; Z: zoledronate; OI: osteogenesis imperfecta 
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Table V Average measurements for distance between 1st and 2nd maxillary molars 
Groups 
(n=6) 
Right (Experimental) 
Mean maxillary molar 
distance (SD) (µm) 
 
Left (control) 
Mean maxillary molar 
distance (SD) (µm) 
 
p-value 
1 91.45 (60.88) 10.04 (14.20) 0.028* 
2 159.60 (84.98) 9.43 (20.46) 0.027* 
3 46.66 (27.13) 0.94  (2.30) 0.028* 
4 46.22 (21.64) 0.94  (2.30) 0.027* 
* p< 0.05 considered statistically significant 
1: osteogenesis imperfecta treated with zoledronate; 2: osteogenesis imperfecta not treated; 3: 
wild type treated with zoledronate; 4: wild type not treated. 
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Figure 17 First and second molar distances during orthodontic tooth movement on right 
maxilla. Increase tooth movement in osteogenesis imperfecta (n=6) compared to wild type 
(n=6).  1: osteogenesis imperfecta treated with zoledronate; 2: osteogenesis imperfecta not 
treated; 3: wild type treated with zoledronate; 4: wild type not treated. 
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Figure 18 3D micro-CT reconstructions of the right maxillas for the OI mouse (i) and wild 
type mouse (ii) after 7 days of tooth movement. A: Anterior; P: Posterior; F: Force; M: Molar 
© Jean Rizkallah 
 
  
 
Discussion 
 
This is the first study of orthodontic tooth movement on an osteogenesis imperfecta 
animal model. Bone cell function and the remodeling mechanisms which normally maintain 
bone homeostasis are altered in OI.29 Orthodontic tooth movement depends on the underlying 
processes of alveolar bone remodeling.30, 31 In light of this, we hypothesized that OI might 
affect OTM. Our results demonstrated that OI mice presented a greater amount of tooth 
movement than control mice. Interestingly, the results were opposite to the original hypothesis 
that OTM would be inhibited in mice with OI. The original reasoning was that the mutant 
collagen would disrupt the mechanotransduction processes during force application and thus, 
reduce tooth movement. However, our results suggest that tooth movement is not only 
possible in OI but also accelerated. Increased tooth movement in mice with OI could be due to 
the lower density of cortical bone and higher bone turnover. 
 Furthermore, the standard deviations for the osteogenesis imperfecta groups were 
larger than the controls. This observation could be explained by the variable penetrance of the 
collagen mutation. Assuming the fact that the disease affected the OI mice differently, we 
could also expect a difference in tooth movement in these mice. Since the standard deviations 
for the wild type groups were reduced, we assumed that the procedure was well controlled. 
The large standard deviations found in the OI groups could not be explained by a faulty 
procedure. Therefore, we hypothesized that the standard deviations observed in the OI groups 
are a reflection of the variance in the disease penetrance. 
 We also observed more dental tipping in the OI mice compared to the control mice. 
One of the factors that affect tooth movement is the supporting bone. A softer bone will move 
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the center of resistance of the tooth more apically. Since the point of application of the force is 
the same in all mice, a larger distance between the force and the center of resistance would 
result in more dental tipping. 
The effect of bisphosphonates on OTM has been studied extensively. It has previously 
been reported that bisphosphonates inhibit tooth movement.8, 32 This is the first study to 
investigate the effect of zoledronate on OTM in OI. Conversely to what is well described in 
the orthodontic literature, our study revealed that zoledronate had no significant inhibiting 
effect on OTM. Previous studies have demonstrated the dose dependent effect of 
bisphosphonates.17, 20 The drug regimen used in this study could be described as a relatively 
low systemic dose. A probable explanation for our results is that the dosage of zoledronate 
was too low to significantly reduce tooth movement. However, a non-significant tooth 
movement reduction was observed in the OI mice treated with zoledronate. 
Bisphosphonates are commonly used to treat patients affected with OI. The typical 
mode of administration is chronic intra-venous injections. This study did not investigate the 
effect of multiple doses of zoledronate on OTM in OI. Instead, the purpose of this study was 
to evaluate the effect on OTM of a minimally effective dose to prevent bone loss.33 
Theoretically, bone loss can be limited in mice with OI without significantly inhibiting tooth 
movement. Bisphosphonates are highly potent drugs with possible side effects like 
osteonecrosis of the jaw. A noble goal would be to evaluate the minimal dose to maintain the 
positive effects while minimizing the side effects. The effect of chronic administration of 
bisphosphonates on OTM in mice with OI was not evaluated in this study. 
These results clearly demonstrate that OTM is accelerated in mice with osteogenesis 
imperfecta in the absence of other factors. It is difficult to draw any conclusions from this 
 39 
study on humans. However, one could hypothesize that orthodontic tooth movement would 
also be accelerated in humans affected by OI in the absence of bisphosphonates. If the latter 
was proven to be true, then orthodontic treatment could be offered to patients affected by OI. 
What remains unclear is the effect of bisphosphonates in OI during orthodontic treatment. This 
question requires more extensive research.  
Study limitations 
There are several limitations to acknowledge. The low dosage of bisphosphonates in 
our protocol did not permit to evaluate a significant inhibiting effect on tooth movement; 
future studies may consider looking at different dosages of bisphosphonates. No biochemical 
tests were performed on the mice to analyze the blood level of zoledronate. Furthermore, our 
groups were relatively small; and although an inhibiting effect of OTM was noticed in OI 
treated with zoledronate, it was not significant. Due to a lack of time and resources we were 
only able to study one time point, after 7 days; future studies could consider looking at 
different timepoints.  
Difficulties encountered 
This study also had its share of difficulties. Breeding of the OI mice was a long process 
and the OI pups had a lower survival rate. Another issue was maintaining mouse body weight. 
Different strategies were combined to minimize weight loss. First, the mice were given a soft 
food diet 3 days prior to the procedure and during the entire length of the study. And second, 
daily injections of saline and analgesics were administered for the first 4 days following the 
surgery. Furthermore, the intra-oral appliance survival was also an issue due to coil breakage. 
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In order to palliate the latter issue, we added more cement on the anterior portion of the coil 
and trimmed the lower incisors.  
Future studies 
Future studies could look at the effect on OTM of multiple systemic doses of 
zoledronate administered in an OI mouse model, for example, 3 weeks, 2 weeks, 1 week and 1 
day prior to starting OTM. It would also be interesting to compare with WT groups and 
evaluate if the inhibiting effect of zoledronate on OTM is similar in both OI and WT mice. 
With the current micro-CT data, we could study bone height, bone width and compare 
between groups.  
It would also be interesting to study bone density, however, that would require redoing 
the CT scans of the entire sample. This data would allow us to evaluate the center of resistance 
of the molars and could explain the observation of increased tooth tipping that was noticed in 
OI.  
Furthermore, an immunohistochemical analyses would answer many questions that 
pertain to quantity of osteoclasts and osteoblasts. Markers such as TRAP can be used to 
identify osteoclasts and Runx2 to identify osteoblasts. Bril could also be used to identify new 
bone formation. 
  
 
Conclusion 
 
Orthodontic tooth movement is increased in mice with osteogenesis imperfecta. A 
unique low systemic dose administered one day prior to force application had no significant 
effect on OTM. These results give further evidence to the dose dependent effect of 
bisphosphonates. Future studies using immunohistochemistry might help elucidate the 
underlying cellular mechanisms of orthodontic tooth movement in mice with OI. 
 
 
 
i 
Bibliography 
 
1. Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives on osteogenesis 
imperfecta. Nat Rev Endocrinol 2011;7(9):540-57. 
2. Cheung MS, Glorieux FH. Osteogenesis Imperfecta: update on presentation and 
management. Rev Endocr Metab Disord 2008;9(2):153-60. 
3. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004;363(9418):1377-85. 
4. Rizkallah J, Schwartz S, Rauch F, Glorieux F, Vu DD, Muller K, et al. Evaluation of 
the severity of malocclusions in children affected by osteogenesis imperfecta with the 
peer assessment rating and discrepancy indexes. Am J Orthod Dentofacial Orthop 
2013;143(3):336-41. 
5. Kadler KE, Holmes DF, Trotter JA, Chapman JA. Collagen fibril formation. Biochem 
J 1996;316 ( Pt 1):1-11. 
6. Zeitlin L, Fassier F, Glorieux FH. Modern approach to children with osteogenesis 
imperfecta. J Pediatr Orthop B 2003;12(2):77-87. 
7. Albright JA. Systemic treatment of osteogenesis imperfecta. Clin Orthop Relat Res 
1981(159):88-96. 
8. Ghoneima AA, Allam ES, Zunt SL, Windsor LJ. Bisphosphonates treatment and 
orthodontic considerations. Orthodontics & craniofacial research 2010;13(1):1-10. 
9. Russell RG. Bisphosphonates: the first 40 years. Bone 2011;49(1):2-19. 
10. Abela S, Chotai M, Bister D. What you need to know about bisphosphonates: an 
overview and general recommendations for orthodontic treatment. Journal of 
orthodontics 2012;39(3):186-92. 
11. Zahrowski JJ. Bisphosphonate treatment: an orthodontic concern calling for a 
proactive approach. Am J Orthod Dentofacial Orthop 2007;131(3):311-20. 
12. Rizzolo D, Sedrak M. Managing the adverse effects of bisphosphonate therapy on the 
jaw. JAAPA 2009;22(11):48-52. 
13. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone 
(osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and 
treatment. Journal of oral and maxillofacial surgery : official journal of the American 
Association of Oral and Maxillofacial Surgeons 2005;63(11):1567-75. 
14. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated 
osteonecrosis of mandibular and maxillary bone: an emerging oral complication of 
supportive cancer therapy. Cancer 2005;104(1):83-93. 
15. Malmgren B, Astrom E, Soderhall S. No osteonecrosis in jaws of young patients with 
osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med 
2008;37(4):196-200. 
16. Igarashi K, Mitani H, Adachi H, Shinoda H. Anchorage and retentive effects of a 
bisphosphonate (AHBuBP) on tooth movements in rats. Am J Orthod Dentofacial 
Orthop 1994;106(3):279-89. 
 
 
ii 
17. Fujimura Y, Kitaura H, Yoshimatsu M, Eguchi T, Kohara H, Morita Y, et al. Influence 
of bisphosphonates on orthodontic tooth movement in mice. European journal of 
orthodontics 2009;31(6):572-7. 
18. Schwartz JE. Ask us: Some drugs affect tooth movement. Am J Orthod Dentofacial 
Orthop 2005;127(6):644. 
19. Rinchuse DJ, Sosovicka MF, Robison JM, Pendleton R. Orthodontic treatment of 
patients using bisphosphonates: a report of 2 cases. Am J Orthod Dentofacial Orthop 
2007;131(3):321-6. 
20. Kaipatur NR, Wu Y, Adeeb S, Stevenson TR, Major PW, Doschak MR. Impact of 
bisphosphonate drug burden in alveolar bone during orthodontic tooth movement in a 
rat model: a pilot study. Am J Orthod Dentofacial Orthop 2013;144(4):557-67. 
21. Giovanelli S, Festa F. Effect of electric stimulation on tooth movement in clinical 
application. In: Davidovitch Z, Norton LA, eds. Biological Mechanisms of Tooth 
Movement and Craniofacial Adaptation. Boston: Harvard Society for Advancement of 
Orthodontics; 1996. 
22. Proffit W, Fields H, Sarver D. Contemporary Orthodontics. Philadelphia, PA: Elsevier; 
2007. 
23. Krishnan V, Davidovitch Z. On a path to unfolding the biological mechanisms of 
orthodontic tooth movement. Journal of dental research 2009;88(7):597-608. 
24. Li J, Zhao Z, Wang J, Chen G, Yang J, Luo S. The role of extracellular matrix, 
integrins, and cytoskeleton in mechanotransduction of centrifugal loading. Mol Cell 
Biochem 2008;309(1-2):41-8. 
25. Bonewald LF, Johnson ML. Osteocytes, mechanosensing and Wnt signaling. Bone 
2008;42(4):606-15. 
26. Bakker AD, Soejima K, Klein-Nulend J, Burger EH. The production of nitric oxide 
and prostaglandin E(2) by primary bone cells is shear stress dependent. J Biomech 
2001;34(5):671-7. 
27. Wang JH, Thampatty BP, Lin JS, Im HJ. Mechanoregulation of gene expression in 
fibroblasts. Gene 2007;391(1-2):1-15. 
28. Masella RS, Meister M. Current concepts in the biology of orthodontic tooth 
movement. Am J Orthod Dentofacial Orthop 2006;129(4):458-68. 
29. Rauch F, Lalic L, Roughley P, Glorieux FH. Relationship between genotype and 
skeletal phenotype in children and adolescents with osteogenesis imperfecta. Journal of 
bone and mineral research : the official journal of the American Society for Bone and 
Mineral Research 2010;25(6):1367-74. 
30. Krishnan V, Davidovitch Z. Cellular, molecular, and tissue-level reactions to 
orthodontic force. Am J Orthod Dentofacial Orthop 2006;129(4):469 e1-32. 
31. Wise G, King G. Mechanisms of tooth eruption and orthodontic tooth movement. 
Journal of dental research 2008;87(5):414-34. 
32. Iglesias-Linares A, Yanez-Vico RM, Solano-Reina E, Torres-Lagares D, Gonzalez 
Moles MA. Influence of bisphosphonates in orthodontic therapy: Systematic review. J 
Dent 2010;38(8):603-11. 
33. Lloyd SA, Travis ND, Lu T, Bateman TA. Development of a low-dose anti-resorptive 
drug regimen reveals synergistic suppression of bone formation when coupled with 
disuse. J Appl Physiol 2008;104(3):729-38. 
 
 
iii 
 
 
